Frontlight ResearchEarly access
WithdrawnNo phase
The Phosphodiesterase 5 Inhibitor Sildenafil as an Adjunct to Antidepressants in Major Depressive Disorder Patients
Key facts
- Who runs it
- Sadat City University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Started
- 1 Jan 2020
- Ended
- 31 Dec 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Sildenafil Citrate
- Placebo oral tablet
- Record updated
- 14 July 2025
- Why it stopped
- Institutional and funding constrains
Who can take part
- Age
- 18 years to 60 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Eighty adult outpatients with the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) diagnosis of MDD based on a MINI Neuropsychiatric Interview (MINI) (American Psychiatric Association., 2000; Sheehan et al., 1998), without psychotic features and a total 17 item HAM-D score of at least 18 with item 1 (depressed mood) scored 2 or greater were eligible (Hamilton, 1960)
- Patients were requested to be free of all the psychotropic and anti-inflammatory medications for at least 4 weeks before participating in the study
Who cannot take part
- Patients with concurrent active medical condition
- Patients with history of receiving Electroconvulsive therapy (ECT)
- Patients with bipolar I or bipolar II disorder
- Patients with personality disorders
- Patients with eating disorders
- Patients with history of seizures
- Patients with inflammatory disorders
- Patients with allergy or contraindications to the used medications
- Cardiovascular disorders
- Moderate or severe hepatic impairment
- Severe renal impairment: creatinine clearance of ≤ 25 ml/min
- Patients with substance dependence or abuse
- Patients with finally pregnant or lactating females
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Antidepressant-like effects of sildenafil to its ability to modulate transduction pathways responsible for neuroplasticity. Treatment with sildenafil was shown to be PKG-dependent and lead to increased expression of cGMP, pCREB, BDNF and VGF in the hippocampus and prefrontal cortex (PFC), brain areas relevant to mood disorders pathophysiology. Sildenafil produces antidepressant-like effects by inhibiting oxidative stress in the hippocampus and by decreasing the levels of IL-1β in the hippocampus and striatum.
The 2 groups in the trial
- Control groupPlacebo, for comparison
Escitalopram 20 mg tablet plus one placebo tablet
Treatment: Placebo oral tablet
- Sildenafil groupTreatment being tested
Escitalopram 20 mg tablet plus one Sildenafil 50 mg tablet
Treatment: Sildenafil Citrate
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Phosphodiesterase 5 Inhibitor Sildenafil as an Adjunct to Antidepressants in Major Depressive Disorder Patients: Randomized, Double-Blind, Placebo-Controlled Trial
- Record updated
- 14 July 2025